The median PFS from HL patients treated with anti-PD-1 echoed the ORR of the CHECKMATE 205 and KEYNOTE 087 studies, in which the median PFS was 14.7 and 13.7 and the ORR was 69.0% and 51.4%, respectively [6,7]. This evidence concerns the gene PDCD1 and Hodgkins lymphoma.